Gene-culture co-evolution emphasizes the joint role of culture and genes for the emergence of altruistic and cooperative behaviors and behavioral genetics provides estimates of their relative importance. However, these approaches cannot assess which biological traits determine altruism or how. We analyze the association between altruism in adults and the exposure to prenatal sex hormones, using the second-to-fourth digit ratio. We find an inverted U-shaped relation for left and right hands, which is very consistent for men and less systematic for women. Subjects with both high and low digit ratios give less than individuals with intermediate digit ratios. We repeat the exercise with the same subjects seven months later and find a similar association, even though subjects' behavior differs the second time they play the game. We then construct proxies of the median digit ratio in the population (using more than 1000 different subjects), show that subjects' altruism decreases with the distance of their ratio to these proxies. These results provide direct evidence that prenatal events contribute to the variation of altruistic behavior and that the exposure to fetal hormones is one of the relevant biological factors. In addition, the findings suggest that there might be an optimal level of exposure to these hormones from social perspective.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622687 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0060419 | PLOS |
Alzheimers Dement
December 2024
Dementias Platform UK - University of Oxford, Oxford, United Kingdom.
Background: Consumption of the Mediterranean-Dietary Approaches to Stop Hypertension Diet Intervention for Neurodegenerative Delay (MIND) diet has been proposed to support advantageous cognitive outcomes. Intra Individual Variability (IIV) has been suggested as a useful outcome for predicting adverse cognitive outcomes. Executive function (EF) may be particularly susceptible to dietary influence.
View Article and Find Full Text PDFBackground: Recent studies suggest that body mass index (BMI) may overestimate obesity and related cognitive health consequences in some populations due to racial differences in body shape and composition. Conversely, waist-to-hip-ratio (WHR) may better capture cognitive health, because this measure accounts for where body fat accumulates. However, few studies have compared the influence of BMI vs.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Central Clinical School, Monash University, Melbourne, VIC, Australia.
Background: Identifying biomarkers for primary tau pathologies like Progressive Supranuclear Palsy (PSP) is crucial for diagnosis and treatment development. The novel positron emission tomography (PET) radiotracer F-PI-2620 shows promise in detecting tau protein in PSP and this study investigates its correlation with clinical markers.
Methods: We conducted a cross-sectional analysis on 20 patients with clinically diagnosed probable PSP (Richardson's Syndrome), who underwent T1-weighted MRI, lumbar puncture, blood testing, and 0-60 min dynamic F-PI-2620 PET scanning.
Alzheimers Dement
December 2024
Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Background: Alzheimer's disease (AD) is associated with cerebral slowing on electroencephalography (EEG), or a shift in oscillatory power from higher to lower frequencies. This change can be captured as the spectral power ratio (SPR) of alpha and beta over delta and theta: (α+β)/(δ+θ). Prior studies have shown that compared to cognitively unimpaired older adults, the SPR was lower in persons with a clinical diagnosis of dementia due to probable AD and those with a biomarker-confirmed diagnosis of amnestic mild cognitive impairment (aMCI) due to AD, and a lower SPR was associated with worse executive functions scores.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
T3D Therapeutics, Inc., Research Triangle Park, NC, USA.
Background: PIONEER was a Phase 2 randomized, placebo-controlled, multi-center trial evaluating efficacy and safety of the dual PPARδ/γ agonist T3D-959 in patients with mild-to-moderate Alzheimer's disease (AD).
Method: Enrolled patients (N = 250) had mild-to-moderate AD per NIA-AA criteria. No AD biomarker enrollment criteria were defined.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!